Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

I-MAB American Depositary Shares (IMAB)

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/17/2020

Market Cap

86,955,258

Shares Outstanding

191,910,000

Weighted SO

82,623,343

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

BGNE --.--%

KRYS --.--%

IMVT --.--%

MRTX --.--%

FHTX --.--%

STTK --.--%

GLUE --.--%

KYMR --.--%

NRIX --.--%

Beta

1.0780

Last Div

0.0000

Range

0.99-2.536

Chg

0.0700

Avg Vol

232166

Mkt Cap

86955258

Exch

NASDAQ

Country

CN

Phone

86 21 6057 8000

DCF Diff

-1.9651

DCF

3.1301

Div Yield

0.0000

P/S

35.0728

EV Multiple

6.0286

P/FV

0.3758

Div Yield %

0.0000

P/E

-0.6868

PEG

-0.0143

Payout

0.0000

Current Ratio

5.6741

Quick Ratio

5.7177

Cash Ratio

5.2000

DSO

369.2010

DIO

2268.5033

Op Cycle

2637.7043

DPO

4179.9252

CCC

-1542.2209

Gross Margin

1.1628

Op Margin

-44.6407

Pretax Margin

-52.2846

Net Margin

-52.9276

Eff Tax Rate

0.1114

ROA

-0.3598

ROE

-0.4514

ROCE

-0.3602

NI/EBT

1.0123

EBT/EBIT

1.1712

EBIT/Rev

-44.6407

Debt Ratio

0.0512

D/E

0.0779

LT Debt/Cap

0.0456

Total Debt/Cap

0.0723

Int Coverage

-7843.2494

CF/Debt

0.0000

Equity Multi

1.5208

Rec Turnover

0.9886

Pay Turnover

0.0873

Inv Turnover

0.1609

FA Turnover

0.2142

Asset Turnover

0.0068

OCF/Share

0.0000

FCF/Share

0.0000

Cash/Share

29.6620

OCF/Sales

0.0000

FCF/OCF

0.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.3758

P/B

0.3758

P/S

35.0728

P/E

-0.6868

P/FCF

0.0000

P/OCF

0.0000

P/CF

0.0000

PEG

-0.0143

P/S

35.0728

EV Multiple

6.0286

P/FV

0.3758

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation